Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Quarterly results
Appointed director
PUMA BIOTECHNOLOGY, INC. (PBYI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Puma Biotechnology Reports Second Quarter Financial Results"
03/02/2023 8-K Quarterly results
Docs: "Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Puma Biotechnology Reports Third Quarter 2021 Financial Results"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Puma Biotechnology Reports Third Quarter 2020 Financial Results"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Puma Biotechnology Reports First Quarter 2020 Financial Results"
02/20/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Puma Biotechnology Reports Third Quarter 2019 Financial Results"
08/08/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Puma Biotechnology Reports Second Quarter 2019 Financial Results"
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 9, 2019 PUMA BIOTECHNOLOGY, INC. Delaware 001-35703 77-0683487 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 248-6500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e...",
"Puma Biotechnology Reports First Quarter 2019 Financial Results"
02/28/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 1, 2018 PUMA BIOTECHNOLOGY, INC. Delaware 001-35703 77-0683487 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 248-6500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rul...",
"Puma Biotechnology Reports Third Quarter 2018 Financial Results"
08/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 9, 2018 PUMA BIOTECHNOLOGY, INC. Delaware 001-35703 77-0683487 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 248-6500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule ...",
"Puma Biotechnology Reports Second Quarter 2018 Financial Results"
05/09/2018 8-K Quarterly results
Docs: "Puma Biotechnology Reports First Quarter 2018 Financial Results"
03/01/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 1, 2018 PUMA BIOTECHNOLOGY, INC. Delaware 001-35703 77-0683487 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 248-6500 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 1...",
"Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results"
11/09/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Puma Biotechnology Reports Third Quarter 2017 Financial Results"
08/09/2017 8-K Quarterly results
Docs: "Puma Biotechnology Reports Second Quarter 2017 Financial Results"
05/10/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Form 8-K - Current report
05/10/2016 8-K Quarterly results
Docs: "Puma Biotechnology Reports First Quarter 2016 Financial Results"
02/29/2016 8-K Quarterly results
Docs: "Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results"
11/09/2015 8-K Quarterly results
Docs: "Puma Biotechnology Reports Third Quarter 2015 Financial Results"
08/10/2015 8-K Quarterly results
Docs: "Puma Biotechnology Reports Second Quarter 2015 Financial Results"
05/11/2015 8-K Quarterly results
Docs: "Puma Biotechnology Reports First Quarter 2015 Financial Results"
03/02/2015 8-K Quarterly results
Docs: "Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results"
11/10/2014 8-K Quarterly results
Docs: "Puma Biotechnology Reports Third Quarter 2014 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy